Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Akkermansia muciniphila is a next-generation probiotic bacterium that has garnered attention for its role in modulating the gut microbiome and influencing systemic immune responses. Recent preclinical studies, particularly in mouse models, have shown that supplementation with A. muciniphila can reduce airway inflammation and alleviate symptoms in models of allergic asthma and other respiratory allergies. The proposed mechanisms include strengthening the gut barrier, reducing systemic inflammation, and modulating immune cell populations, such as promoting regulatory T cells and decreasing Th2-mediated allergic responses. Some studies have also reported that A. muciniphila can increase the production of short-chain fatty acids, which have anti-inflammatory properties and may influence immune responses in the lung-gut axis.

However, as of mid-2024, evidence in humans is limited. Most data come from animal studies or in vitro experiments, with only a few early-phase clinical trials exploring its effects on allergic diseases. While these findings are promising and suggest a scientific rationale, the lack of robust human clinical trial data limits the strength of the recommendation for using A. muciniphila specifically to treat or support respiratory allergies. Therefore, while there is emerging scientific interest and some supporting data, the overall evidence level remains moderate to low at this time.

More about akkermansia muciniphila
More about Allergies (respiratory)

Other ingredients used for Allergies (respiratory)

Other health conditions supported by akkermansia muciniphila

Products containing akkermansia muciniphila